These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35267618)

  • 1. CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response.
    de Nonneville A; Finetti P; Picard M; Monneur A; Pantaleo MA; Astolfi A; Ostrowski J; Birnbaum D; Mamessier E; Bertucci F
    Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response.
    Boudin L; de Nonneville A; Finetti P; Mescam L; Le Cesne A; Italiano A; Blay JY; Birnbaum D; Mamessier E; Bertucci F
    J Transl Med; 2022 Oct; 20(1):464. PubMed ID: 36221119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDL1 expression is an independent prognostic factor in localized GIST.
    Bertucci F; Finetti P; Mamessier E; Pantaleo MA; Astolfi A; Ostrowski J; Birnbaum D
    Oncoimmunology; 2015 May; 4(5):e1002729. PubMed ID: 26155391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo.
    Geldres C; Savoldo B; Hoyos V; Caruana I; Zhang M; Yvon E; Del Vecchio M; Creighton CJ; Ittmann M; Ferrone S; Dotti G
    Clin Cancer Res; 2014 Feb; 20(4):962-71. PubMed ID: 24334762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells.
    Beard RE; Zheng Z; Lagisetty KH; Burns WR; Tran E; Hewitt SM; Abate-Daga D; Rosati SF; Fine HA; Ferrone S; Rosenberg SA; Morgan RA
    J Immunother Cancer; 2014; 2():25. PubMed ID: 25197555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes.
    Leuci V; Donini C; Grignani G; Rotolo R; Mesiano G; Fiorino E; Gammaitoni L; D'Ambrosio L; Merlini A; Landoni E; Medico E; Capellero S; Giraudo L; Cattaneo G; Iaia I; Pignochino Y; Basiricò M; Vigna E; Pisacane A; Fagioli F; Ferrone S; Aglietta M; Dotti G; Sangiolo D
    Clin Cancer Res; 2020 Dec; 26(23):6321-6334. PubMed ID: 32900797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy.
    Nota SPFT; Osei-Hwedieh DO; Drum DL; Wang X; Sabbatino F; Ferrone S; Schwab JH
    Front Oncol; 2022; 12():939166. PubMed ID: 36110930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSPG4-targeting CAR-macrophages inhibit melanoma growth.
    Greiner D; Xue Q; Waddell TQ; Kurudza E; Belote RL; Dotti G; Judson-Torres RL; Reeves MQ; Cheshier SH; Roh-Johnson M
    bioRxiv; 2024 Jun; ():. PubMed ID: 38895447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors.
    Wang Y; Geldres C; Ferrone S; Dotti G
    Expert Opin Ther Targets; 2015; 19(10):1339-50. PubMed ID: 26190756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T Cells.
    Harrer DC; Schenkel C; Berking C; Herr W; Abken H; Dörrie J; Schaft N
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
    Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
    [No Abstract]   [Full Text] [Related]  

  • 12. CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia.
    Harrer DC; Schuler G; Dörrie J; Schaft N
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31195686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma.
    Chen X; Habib S; Alexandru M; Chauhan J; Evan T; Troka JM; Rahimi A; Esapa B; Tull TJ; Ng WZ; Fitzpatrick A; Wu Y; Geh JLC; Lloyd-Hughes H; Palhares LCGF; Adams R; Bax HJ; Whittaker S; Jacków-Malinowska J; Karagiannis SN
    Cancers (Basel); 2024 Sep; 16(19):. PubMed ID: 39409881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors.
    Rusakiewicz S; Semeraro M; Sarabi M; Desbois M; Locher C; Mendez R; Vimond N; Concha A; Garrido F; Isambert N; Chaigneau L; Le Brun-Ly V; Dubreuil P; Cremer I; Caignard A; Poirier-Colame V; Chaba K; Flament C; Halama N; Jäger D; Eggermont A; Bonvalot S; Commo F; Terrier P; Opolon P; Emile JF; Coindre JM; Kroemer G; Chaput N; Le Cesne A; Blay JY; Zitvogel L
    Cancer Res; 2013 Jun; 73(12):3499-510. PubMed ID: 23592754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma.
    Riccardo F; Tarone L; Iussich S; Giacobino D; Arigoni M; Sammartano F; Morello E; Martano M; Gattino F; Maria R; Ferrone S; Buracco P; Cavallo F
    Ther Adv Med Oncol; 2019; 11():1758835919855491. PubMed ID: 31217827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSPG4: a prototype oncoantigen for translational immunotherapy studies.
    Rolih V; Barutello G; Iussich S; De Maria R; Quaglino E; Buracco P; Cavallo F; Riccardo F
    J Transl Med; 2017 Jul; 15(1):151. PubMed ID: 28668095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4.
    Wang X; Katayama A; Wang Y; Yu L; Favoino E; Sakakura K; Favole A; Tsuchikawa T; Silver S; Watkins SC; Kageshita T; Ferrone S
    Cancer Res; 2011 Dec; 71(24):7410-22. PubMed ID: 22021902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors.
    Komita H; Koido S; Hayashi K; Kan S; Ito M; Kamata Y; Suzuki M; Homma S
    Oncol Rep; 2015 Oct; 34(4):2099-105. PubMed ID: 26239720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types.
    Ilieva KM; Cheung A; Mele S; Chiaruttini G; Crescioli S; Griffin M; Nakamura M; Spicer JF; Tsoka S; Lacy KE; Tutt ANJ; Karagiannis SN
    Front Immunol; 2017; 8():1911. PubMed ID: 29375561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical detection of the chondroitin sulfate proteoglycan 4 protein in primary and metastatic melanoma.
    Grossauer A; Uranowska K; Kitzwögerer M; Mostegel M; Breiteneder H; Hafner C
    Oncol Lett; 2023 Sep; 26(3):382. PubMed ID: 37559576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.